Reumatoloxía
Hospital Universitario Virgen Macarena
Sevilla, EspañaPublicacións en colaboración con investigadores/as de Hospital Universitario Virgen Macarena (32)
2024
-
Impact of multimorbidity on the first ts/bDMARD effectiveness and retention rate after two years of follow-up in patients with rheumatoid arthritis from the BIOBADASER registry
Arthritis Research and Therapy, Vol. 26, Núm. 1
-
Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: Real-world data from the BIOBADASER registry
Annals of the Rheumatic Diseases
2022
-
Retention of golimumab treatment following discontinuation of non-TNF inhibitors in patients with inflammatory rheumatic diseases: An analysis of the Spanish BIOBADASER registry
Musculoskeletal Care, Vol. 20, Núm. 2, pp. 403-407
2020
-
Tocilizumab in giant cell arteritis: differences between the GiACTA trial and a multicentre series of patients from the clinical practice
Clinical and experimental rheumatology, Vol. 38, Núm. 2, pp. 112-119
2019
-
Evaluation of 12 GWAS-drawn SNPs as biomarkers of rheumatoid arthritis response to TNF inhibitors. A potential SNP association with response to etanercept
PLoS ONE, Vol. 14, Núm. 2
-
Factors associated with long-term retention of treatment with golimumab in a real-world setting: an analysis of the Spanish BIOBADASER registry
Rheumatology International, Vol. 39, Núm. 3, pp. 509-515
-
Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice
Seminars in Arthritis and Rheumatism, Vol. 49, Núm. 1, pp. 126-135
2018
-
Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients
Seminars in Arthritis and Rheumatism, Vol. 48, Núm. 1, pp. 22-27
-
Efficacy of Tocilizumab in Patients With Moderate-to-Severe Corticosteroid-Resistant Graves Orbitopathy: A Randomized Clinical Trial
American Journal of Ophthalmology, Vol. 195, pp. 181-190
-
Validation study of genetic biomarkers of response to TNF inhibitors in rheumatoid arthritis
PLoS ONE, Vol. 13, Núm. 5
2016
-
Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis
Pharmacogenomics Journal, Vol. 16, Núm. 2, pp. 137-140
2015
-
FCGR polymorphisms in the treatment of rheumatoid arthritis with Fc-containing TNF inhibitors
Pharmacogenomics, Vol. 16, Núm. 4, pp. 333-345
-
Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: A case-only study
Arthritis Research and Therapy, Vol. 17, Núm. 1
2014
-
Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis
Pharmacogenetics and Genomics, Vol. 24, Núm. 5, pp. 238-245
-
Documento práctico para el uso de abatacept subcutáneo
Reumatologia Clinica, Vol. 10, Núm. 4, pp. 218-226
-
Lack of replication of interactions between polymorphisms in rheumatoid arthritis susceptibility: Case-control study
Arthritis Research and Therapy, Vol. 16, Núm. 1
-
Lack of validation of genetic variants associated with anti-tumor necrosis factor therapy response in rheumatoid arthritis: A genome-wide association study replication and meta-analysis
Arthritis Research and Therapy, Vol. 16, Núm. 2
2013
-
El uso de abatacept en artritis reumatoide: Revisión de la evidencia y recomendaciones
Reumatologia Clinica, Vol. 9, Núm. 1, pp. 5-17
-
Le facteur rhumatoïde ne semble pas prédire la réponse aux anti-TNF α dans la polyarthrite rhumatoïde: expérience de trois centres
Revue du Rhumatisme (Edition Francaise)
-
Rheumatoid factor does not predict response to TNF antagonists in rheumatoid arthritis: Three centers experience
Joint Bone Spine